Upcoming Value Driving Events

Corporate Development

• ONCO 5 out licensing: Japan/ROW 2H02

• New strategic alliance: ER/MR/VITD 2H02

• Oncology/dermatology product acquisition 2H02

Select Corporate Partner Milestones

• Wyeth NSP989 Ph I 3Q02 ERA923 Ph III 2H02

• GSK GW516 Ph I 2H02

• Lilly LY929 Ph I 1H02 LYXXX Ph I 4Q02

• TAP LGD2226 Ph I 2H02

Financial

• Positive operating profit 2002

• Capital restructuring: convertible debt 2002

?

?

Previous slide

Next slide

Back to first slide

View graphic version